A retrospective study to determine causes and potential predictors of mortality and to assess risk of major adverse cardiovascular events in patients with Fabry disease treated with alphagalactosidase A in Argentina
Latest Information Update: 13 May 2021
Price :
$35 *
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- 13 May 2021 New trial record